[{"notes_id":"1_1998","category":"9","subcategory":"1","title":"Antipsychotics: monitoring","body":"The monitoring requires for patients taking antipsychotic medication are extensive. This is on top of the clinical follow-up that such patients clearly require. The BNF advises the following*:<br \/><br \/><div class=\"table-responsive\"><table class = \"tlarge table table-striped table-bordered\"  data-role=\"table\" id=\"tableid1\" ><thead><tr><th><b>Test<\/b><\/th><th><b>Frequency<\/b><\/th><\/tr><\/thead><tbody><tr><td>Full blood count (FBC), urea and electrolytes (U&E), liver function tests (LFT)<\/td><td><ul><li>at the start of therapy <\/li><li>annually<\/li><li>clozapine requires much more frequent monitoring of FBC (initially weekly)<\/td><\/tr><tr><td><\/li><\/ul>Lipids, weight<\/td><td><ul><li>at the start of therapy<\/li><li>at 3 months<\/li><li>annually<\/td><\/tr><tr><td><\/li><\/ul>Fasting blood glucose, prolactin<\/td><td><ul><li>at the start of therapy<\/li><li>at 6 months<\/li><li>annually<\/td><\/tr><tr><td><\/li><\/ul>Blood pressure<\/td><td><ul><li>baseline<\/li><li>frequently during dose titration<\/td><\/tr><tr><td><\/li><\/ul>Electrocardiogram<\/td><td><ul><li>baseline<\/td><\/tr><tr><td><\/li><\/ul>Cardiovascular risk assessment<\/td><td><ul><li>annually<\/td><\/tr><\/tbody><\/table><\/div><\/li><\/ul><br \/>*please see the BNF for more details. There are a number of specific recommendations for individual drugs, the above is a general summary","notes_hash":"b0ccfa15adcd33ea82eae697cdb76de7","knowledge_graph_node_id_link":10644,"links":"","media":"","concepts_for_notes":[],"category_name":"Psychiatry \/ Neurology","subcategory_name":"Psychiatry","comment_count":3},"",[]]